Analytical Data
-
Gene name
aiiM
- Application
-
Alternative Names
AHL-lactonase
-
Species
Microbacterium testaceum
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
C6L862
-
Expression Region
1-251aa
-
Molecular Weight
43.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
aIIIM, a novel recombinant protein, has garnered significant interest in the field of biotechnology and medical research due to its potential applications in therapeutic development and diagnostics. Recombinant proteins, produced through genetic engineering techniques, have revolutionized the way we approach various diseases by enabling the production of high-purity proteins that can mimic natural biological functions. The study of aIIIM specifically focuses on its role in modulating immune responses, which is crucial for developing new treatments for autoimmune disorders, cancer immunotherapy, and infectious diseases. Researchers have been investigating the structural characteristics and functional properties of aIIIM to better understand its mechanisms of action and potential interactions with other biomolecules. The advancement in recombinant DNA technology has facilitated the production of aIIIM in significant quantities, paving the way for high-throughput screening and functional assays to evaluate its efficacy and safety. Moreover, the insights gained from studying aIIIM could lead to innovative therapeutic strategies, making it a promising candidate for future clinical applications. As the demand for targeted and personalized medicine continues to rise, aIIIM's discovery may contribute to the development of novel biologics that improve patient outcomes and quality of life.
